KEYNOTE-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic NSCLC

Bookmark and Share
Published: 16 Feb 2021
Views: 91
Rating:
Save
Prof Michael Boyer - Chris O’Brien Lifehouse, Sydney, Australia

Prof Michael Boyer speaks to ecancer about the phase III KEYNOTE-598 study that he presented at the WCLC 2020 meeting.

He explains that KEYNOTE-598 compared the use pembrolizumab with ipilimumab or placebo in patients with non-small cell lung cancer and PD-L1 tumour proportion scores of ≥50%.

Prof Boyer reports that no difference was seen in terms of efficacy of the treatments however an increase in adverse events was seen with the addition of ipilimumab.